Management Change/Compensation Form 8 K

(a)

On December 10, 2024, Yu (Katherine) Xu, Ph.D., tendered her resignation from the Board of Directors (the "Board") of Equillium, Inc. (the "Company") and the Audit Committee of the Board (the "Audit Committee"), effective immediately. Dr. Xu's resignation is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On December 11, 2024, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee"), appointed Barbara Troupin, M.D., as a member of the Company's Audit Committee to fill the vacancy created by Dr. Xu's resignation. The Audit Committee is now composed of Martha Demski (Chair), Bala Manian, Ph.D., and Dr. Troupin.

(d)

On December 11, 2024 (the "Appointment Date"), the Board, upon recommendation of the Nominating Committee, appointed Peter Colabuono as a Class II director of the Company, with a term of office expiring at the 2026 annual meeting of stockholders, to fill the vacancy created by Dr. Xu's resignation. There are no arrangements or understandings between Mr. Colabuono and any other person pursuant to which Mr. Colabuono was selected as a director. In addition, there are no transactions in which Mr. Colabuono has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Pursuant to the Company's Non-EmployeeDirector Compensation Policy (the "Compensation Policy"), Mr. Colabuono (i) will receive an annual cash retainer of $42,000 for service as a member of the Board and (ii) was granted on the Appointment Date, an option to purchase 40,000 shares of common stock, which vests monthly over a three-year period from the date of grant. The Compensation Policy also provides for further automatic annual option grants to purchase 20,000 shares of common stock on the date of each annual meeting of stockholders, which will vest in equal monthly installments over the 12 months following the date of grant. Each of the option grants described above will vest in full in the event of a change in control (as defined in the Company's 2018 Equity Incentive Plan) provided Mr. Colabuono remains in continuous service with the Company as of immediately prior to such change in control. Mr. Colabuono has entered into the Company's standard form of Indemnification Agreement for directors of the Company.